CMO
GCVRZ

Covenant Multifamily Offices’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Covenant Multifamily Offices’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-200
Closed – – 146
2017
Q4 		$0 Buy
+200
New +$76 ﹤0.01% 131

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return

Covenant Multifamily Offices's GCVRZ Position: Q1 2018 in Review

Covenant Multifamily Offices sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2018, closing a stake of 200 shares.

Covenant Multifamily Offices first reported a position in GCVRZ in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 100 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2018.

  • Covenant Multifamily Offices reported no remaining Sanofi Contingent Value Rights position as of Q1 2018 after selling out during the quarter.
  • Covenant Multifamily Offices sold 200 Sanofi Contingent Value Rights shares in Q1 2018.
  • Covenant Multifamily Offices first reported a position in Sanofi Contingent Value Rights in Q4 2017 and held it in 1 quarter.
  • Covenant Multifamily Offices's Sanofi Contingent Value Rights position peaked at $0 in Q4 2017.
  • 100 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2018.

Based on Covenant Multifamily Offices's 13F filing for Q1 2018, filed 23 Apr 2018.